Pulmonary Research & Clinical Trials
Our Pulmonary teams are committed to continuing improvement on care initiatives and solutions for chronic respiratory conditions. They lead several ongoing clinical trials, and aid in the advancement of new technology, diagnostic solution and medication management opportunities.
For Patients
If you have been diagnosed with pulmonary diseases such as Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Fibrosis, or Pulmonary Hypertension you may be eligible to participate in a clinical research trial. Clinical research trials take place at both the East and West locations for The Oregon Clinic Pulmonary, Critical Care & Sleep Medicine.
There are different types of clinical trials you can be involved with. To learn more about the world of research, we highly recommend reading more on the U.S. National Library of Medicine website by clicking here.
If you are interested in participating in a research trial, please call the contact info that corresponds with your diagnosed disease for more information.
Pulmonary, Critical Care & Sleep Medicine East
- Asthma
- COPD
- Lung Nodule
- Idiopathic Pulmonary Fibrosis
- Interstitial Lung Disease
- Pulmonary Hypertension
Contact: Meg Day | 503-963-3182 | Email
Pulmonary, Critical Care & Sleep Medicine – West
- Asthma
- Pulmonary Hypertension
Contact: Pulmonary, Critical Care & Sleep Medicine West | 503-297-3778
For Health Professionals
AstraZeneca D3250R00023 Severe Asthma
* Currently closed to additional participants*
The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individual with Severe Asthma in the United States.
18 + year old, with minimum 12-month diagnosis of uncontrolled or under-controlled severe asthma on high-dose ICS with additional controllers.
aTyr 19230C-004
Meg Day I 503-963-3182 I Email
A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous Efzofitimod in patients with pulmonary sarcoidosis.
Enrolling 18+ year old subjects with a confirmed diagnosis of pulmonary sarcoidosis for at least 6 months. Patients must be receiving oral corticosteroid for at least 3 months prior to screening, at a dose between 7.5 and 25 mg a day, and at a stable dose for at least 4 weeks prior to randomization. Patients must be willing to attempt a taper of oral corticosteroids to 0mg/day.
Biodesix BDX-CD-003 (Altitude)
Meg Day I 503-963-3182 I Email
A multicenter, randomized controlled trial, prospectively evaluating the clinical utility of the Nodify XL2®Proteomic Classifier in newly discovered low to moderate risk lung nodules
Enrolling 40+ year old subjects with newly identified solid lung nodules between 8 and 30mm. A CT scan identifying the lung nodule of concern must have been performed within 60 days of enrollment. Subjects with prior history of lung cancer are excluded.
FIBRONEER 1305-0014
* Currently closed to additional participants*
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in people with Idiopathic Pulmonary Fibrosis (IPF)
Enrolling 40+ year old subjects with Idiopathic Pulmonary Fibrosis (IPF), on stable treatment of nintedanib or pirfenidone for at least 12 weeks or not on nintedanib or pirfenidone treatment for at least 8 weeks. With Forced Vital Lung Capacity (FVC) ≥45% of predicted normal and Diffusing Capacity for Carbon Monoxide (DLCO) ≥25% and <90% predicted of normal.
F. Hoffmann-La Roche Ltd GB44332 ARNASA
Meg Day I 503-963-3182 I Email
A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Astegolimab in patients with chronic obstructive pulmonary disease (COPD)
Enrolling 40–80-year-old subjects with documented COPD diagnosis for at least 12 months and a history of frequent exacerbations (at least 2 in past 12 months). Subjects must be on optimized COPD maintenance therapy for at least 12 months prior to screening and not require more than 4.0 liters/min of supplemental oxygen.
FIBRONEER 1305-0023
Meg Day I 503-963-3182 I Email
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung diseases.
Enrolling 18+ year old subjects with Interstitial Lung Disease (ILD) other than Idiopathic Pulmonary Fibrosis (IPF), on stable treatment of nintedanib for at least 12 weeks or not on nintedanib treatment for at least 8 weeks. With Forced Vital Lung Capacity (FVC) ≥45% of predicted normal and Diffusing Capacity for Carbon Monoxide (DLCO) ≥25% and <90% predicted of normal.
Janssen/Actelion AC-055-315 UNISUS
Meg Day I 503-963-3182 I Email
A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerability of Macitentan 75mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension, Followed by an Open-label Treatment Period with Macitentan 75mg
Enrolling 18+ year old subjects with documented PAH Can be idiopathic, heritable, drug or toxin-induced or related to HIV or CTD. Must be able to complete 6mwt of 50-440 meters
PHAR Pulmonary Hypertension Association Registry
Meg Day I 503-963-3182 I Email
A multicenter, prospective registry of newly evaluated patients at PHCCs in the United States who have either PAH or CTEPH.
Baseline information will be collected at the time of initial evaluation at the PHCC with follow-up data collected at approximately 6-month intervals.
United Therapeutics
Meg Day I 503-963-3182 I Email
A Randomized, Double-Blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis
IPF diagnosis per 2018 ATS guidelines. FVC > 45% at screening, FEV1/FVC > 0.70, can be on current IPF therapy if stable x 30 days. No azathioprine, corticosteroids >20mg/day, cyclophosphamide, or rituximab.